RDP PROMPT AG is a privately held biotech company developing therapeutics that identify and degrade intrinsically disordered region (IDR) proteins using the PromptDegrader™ protein modulation platform. Its projects include an E7 degrader targeting the HPV E7 oncoprotein, research on MYC, and other programs such as CROMOC and CP201.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Targeted Protein Degradation Platform (PromptDegrader™)
First-in-class platform for targeted protein degradation of intrinsically disordered protein regions; small-molecule degraders for oncology, neurology, immune response, virology and aging.
HPV-E7 Protein Degrader
Oral, small-molecule-based degrader against the HPV-associated E7 oncoprotein; developed for HPV-driven malignancies as monotherapy or combination therapy.
c-Myc-Targeted Degradation Therapeutics
c-Myc-targeted degradation therapeutics based on PromptDegrader™; oral monovalent small-molecule degraders and early RNA disruptor approaches for oncology indications.
Knowledge
No knowledge articles yet
Once RDP PROMPT AG has claimed this profile, we'll publish editorial articles and case studies here together.